StreetInsider.com News Articles

Form 424B2 Opus Genetics, Inc.

Wed, 17 Jun 2026 07:26:00 -0400

si-local-file:///var/storage/secattach/20260617/26656829.html

Form 424B2 Opus Genetics, Inc.

Wed, 17 Jun 2026 07:26:00 -0400

si-local-file:///var/storage/secattach/20260617/26656829.html

H.C. Wainwright Reiterates Buy Rating on Opus Genetics (IRD)

Wed, 17 Jun 2026 06:49:45 -0400

H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating and $8.00 price target on Opus Genetics (NASDAQ: IRD).

The analyst commented: "Opus Genetics hosted a KOL webinar and discussion highlighting the company’s inherited retinal disease (IRD) gene therapy pipeline including: (1) preclinical programs targeting RDH12, MERTK, and RHO mutations; as well as (2) ongoing development for the LCA5 and BEST1 clinical programs. We emphasize the therapeutic goal across programs is to restore vision and stop blindness progression through AAV-based one-time durable subretinal gene therapy delivery, respectively coding for the compromised protein expression otherwise driving retinal degeneration. Among these IRD programs, targeting

Form EFFECT Opus Genetics, Inc.

Wed, 17 Jun 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260617/26656418.html

Form EFFECT Opus Genetics, Inc.

Wed, 17 Jun 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260617/26656418.html

Opus Genetics (IRD) Reiterated at Market Outperform by Citizens after R&D Day

Wed, 17 Jun 2026 04:19:57 -0400

Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $11.00 price target on Opus Genetics (NASDAQ: IRD).

The analyst commented, "Opus’s R&D Day was impressive not only for the retinal expert star power assembled, but for the clear and detailed messaging for the future growth of the company over the midto-long term. Management has assembled a pipeline of attractive gene therapy candidates and developed a clinical and regulatory strategy that should allow for accelerated paths to approval. First up is OPGx-LCA5, where new two-year data unveiled at the R&D Day support a durable benefit, which we expect to last for

Form 8-K Opus Genetics, Inc. For: Jun 16

Tue, 16 Jun 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260616/26654207.html

Form 8-K Opus Genetics, Inc. For: Jun 16

Tue, 16 Jun 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260616/26654207.html

Opus Genetics outlines five gene therapy programs for retinal diseases

Tue, 16 Jun 2026 16:06:08 -0400

Opus Genetics, Inc. (NASDAQ: IRD) held a Research and Development Science Forum on June 16, 2026, where management presented updates on five gene therapy programs targeting inherited retinal diseases (IRDs).

The company said three programs — OPGx-RDH12, OPGx-MERTK, and OPGx-RHO — are expected to enter clinical testing within the next 12 to 18 months. OPGx-RDH12, targeting a severe form of Leber congenital amaurosis, is expected to begin U.S. clinical testing in the fourth quarter of 2026, with funding supported by the RDH12 Alliance. OPGx-MERTK, targeting autosomal recessive retinitis pigmentosa, is expected to initiate clinical testing at the Cleveland Clinic Abu Dhabi

Opus Genetics outlines five gene therapy programs for retinal diseases

Tue, 16 Jun 2026 16:06:08 -0400

Opus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases

Tue, 16 Jun 2026 16:05:00 -0400

Rapidly Advancing Five IRD Programs with Four Clinical Data Readouts Expected in 2027

RDH12, MERTK and RHO Programs Expected to Enter Clinical Testing over the Next 12 to 18 Months

Cash Runway into 2029 Expected to Fund Multiple Clinical Inflection Points, Potential Product Approvals and Opportunities for Priority Review Vouchers

IRD Prevalence Across Select Global Markets Provides a Significant Commercial Opportunity Across Opus Genetics’ Pipeline

RESEARCH TRIANGLE PARK, N.C., June 16, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”),

Opus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases

Tue, 16 Jun 2026 16:05:00 -0400

Rapidly Advancing Five IRD Programs with Four Clinical Data Readouts Expected in 2027

RDH12, MERTK and RHO Programs Expected to Enter Clinical Testing over the Next 12 to 18 Months

Cash Runway into 2029 Expected to Fund Multiple Clinical Inflection Points, Potential Product Approvals and Opportunities for Priority Review Vouchers

IRD Prevalence Across Select Global Markets Provides a Significant Commercial Opportunity Across Opus Genetics’ Pipeline

RESEARCH TRIANGLE PARK, N.C., June 16, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”),

Opus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases

Tue, 16 Jun 2026 16:05:00 -0400

Rapidly Advancing Five IRD Programs with Four Clinical Data Readouts Expected in 2027

RDH12, MERTK and RHO Programs Expected to Enter Clinical Testing over the Next 12 to 18 Months

Cash Runway into 2029 Expected to Fund Multiple Clinical Inflection Points, Potential Product Approvals and Opportunities for Priority Review Vouchers

IRD Prevalence Across Select Global Markets Provides a Significant Commercial Opportunity Across Opus Genetics’ Pipeline

RESEARCH TRIANGLE PARK, N.C., June 16, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”),

Opus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases

Tue, 16 Jun 2026 16:05:00 -0400

Rapidly Advancing Five IRD Programs with Four Clinical Data Readouts Expected in 2027

RDH12, MERTK and RHO Programs Expected to Enter Clinical Testing over the Next 12 to 18 Months

Cash Runway into 2029 Expected to Fund Multiple Clinical Inflection Points, Potential Product Approvals and Opportunities for Priority Review Vouchers

IRD Prevalence Across Select Global Markets Provides a Significant Commercial Opportunity Across Opus Genetics’ Pipeline

RESEARCH TRIANGLE PARK, N.C., June 16, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”),

Form 8-K Opus Genetics, Inc. For: Jun 16

Tue, 16 Jun 2026 12:06:00 -0400

si-local-file:///var/storage/secattach/20260616/26652749.html

Form 8-K Opus Genetics, Inc. For: Jun 16

Tue, 16 Jun 2026 12:06:00 -0400

si-local-file:///var/storage/secattach/20260616/26652749.html

Opus Genetics (IRD) Reiterated at Market Outperform by Citizens After Investor Meet

Mon, 15 Jun 2026 05:11:16 -0400

Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $11.00 price target on Opus Genetics (NASDAQ: IRD).

The analyst commented, "We came out of our meetings with a better understanding of Opus’s big picture plans, which involve a quick, relatively inexpensive, and flexible development strategy that should be applicable across programs. As the lead candidate, OPGx-LCA5 has our highest POS at 60%, and despite a relatively modest peak sales opportunity (we model ~$150M in peak WW sales), the program will derisk the regulatory strategy and allow Opus to build out its commercial infrastructure, which will have synergistic overlap with the

Form S-3 Opus Genetics, Inc.

Fri, 05 Jun 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260605/26611619.html

Form S-3 Opus Genetics, Inc.

Fri, 05 Jun 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260605/26611619.html

Guggenheim Starts Opus Genetics (IRD) at Buy

Thu, 04 Jun 2026 06:10:07 -0400

Guggenheim analyst Debjit Chattopadhyay initiates coverage on Opus Genetics (NASDAQ: IRD) with a Buy rating and a price target of $16.00.

For an analyst ratings summary and ratings history on Opus Genetics click here. For more ratings news on Opus Genetics click here.

Shares of Opus Genetics closed at $4.20 yesterday.

Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts

Tue, 02 Jun 2026 07:00:00 -0400

RESEARCH TRIANGLE PARK, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced the guest speakers for its virtual Research & Development (R&D) Science Forum to be held on Tuesday, June 16, 2026, from 10:00 am – 12:00 pm ET.